News
NWPHF
2.100
NaN%
--
Newron Pharma price target lowered to CHF 44 from CHF 48 at H.C. Wainwright
TipRanks · 05/04 10:16
FDA halts U.S. recruitment in Newron’s key schizophrenia trial after patient death
TipRanks · 04/29 16:05
Newron Shareholders Back Board Changes at 2026 General Meeting
TipRanks · 04/23 13:35
Newron Pharmaceuticals’ Earnings Call Signals Pivotal Year Ahead
TipRanks · 03/27 00:18
Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright
TipRanks · 03/25 10:16
Newron bolsters finances as Evenamide enters pivotal global Phase III
TipRanks · 03/24 06:34
Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul
TipRanks · 03/24 06:33
Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress
TipRanks · 03/20 06:33
Newron extends EIB loan maturities to align financing with Evenamide milestones
TipRanks · 03/19 06:35
Newron refreshes board with CNS and capital markets experts ahead of AGM
TipRanks · 03/18 06:34
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide
TipRanks · 02/16 17:02
Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug
TipRanks · 02/16 17:02
Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia
TipRanks · 02/03 06:33
Analysts Conflicted on These Healthcare Names: Arcturus Therapeutics (ARCT), Newron Pharmaceuticals SpA (OtherNWPHF) and Aldeyra Therapeutics (ALDX)
TipRanks · 01/21 15:20
Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright
TipRanks · 01/12 11:10
EA Pharma Starts Phase III Trial of Newron’s Evenamide for Treatment‑Resistant Schizophrenia in Japan
TipRanks · 01/07 06:33
Newron Secures EU Patent Extension for Lead Schizophrenia Drug Evenamide
TipRanks · 01/06 06:33
Newron Wins Long-Term EU Patent Protection for Lead Schizophrenia Drug Evenamide
TipRanks · 01/06 06:32
Newron Pharma initiated with a Buy at Lucid Capital
TipRanks · 12/11/2025 11:50
Newron Pharmaceuticals’ Evenamide Advances with ENIGMA-TRS 2 Trial: Analyst Reiterates Buy Rating
TipRanks · 12/11/2025 11:16
More
Webull provides a variety of real-time NWPHF stock news. You can receive the latest news about Newron Phar through multiple platforms. This information may help you make smarter investment decisions.
About NWPHF
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.